Qorvo
QRVO
114.17
0.00
0.00%
Qorvo
US · QRVO
#1460 by market cap
Listed 1970
114.17
0.00
0.00%
Live - 5344 symbols - heartbeat 7s ago
· 2026-10-07 19:54
- Market cap
- 10.07B
- P/E (TTM)i
- 26.49
- P/Bi
- 2.90
- EPSi
- 3.62
- Div yieldi
- 0.00%
- 52W posi
- 85%
Reader sentiment
Are you bullish or bearish on QRVO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.68, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -1.09% YoY
Margins
- Gross margin
- 45.89%
- Operating margin
- 13.42%
- Net margin
- 9.22%
Key ratios & quality
- PEG ratioi
- 0.54
- Altman Z-Scorei
- 3.68
PEG uses trailing P/E against the 3-year net income growth rate (48.67%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.09B | 3.24B | 4.02B | 4.65B | 3.57B | 3.77B | 3.72B | 3.68B |
| Gross profit | 1.20B | 1.32B | 1.88B | 2.29B | 1.30B | 1.49B | 1.54B | 1.69B |
| Selling & admin expenses | 476.07M | 343.57M | 367.24M | 349.72M | 358.79M | 389.14M | 403.62M | 380.67M |
| Research & development | 450.48M | 484.41M | 570.40M | 623.64M | 649.84M | 682.25M | 747.71M | 726.12M |
| Operating profit | 216.47M | 423.22M | 906.63M | 1.27B | 195.58M | 313.12M | 288.10M | 493.79M |
| Pretax profit | 91.79M | 395.09M | 807.38M | 1.18B | 124.63M | 73.56M | 65.90M | 398.27M |
| Tax | -41.33M | 60.76M | 73.77M | 147.73M | 21.48M | 143.88M | 10.28M | 59.28M |
| Net profit | 133.13M | 334.33M | 733.61M | 1.03B | 103.15M | -70.32M | 55.62M | 338.99M |
| Basic EPS | 1 | 3 | 6 | 9 | 1 | -1 | 1 | 4 |
| Diluted EPS | 1.05 | 2.80 | 6.32 | 9.26 | 1.00 | -0.72 | 0.58 | 3.62 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 869.47M | 818.78M | 1.06B | 992.96M | 808.28M | 784.80M |
| Gross profit | 366.56M | 331.80M | 497.09M | 464.19M | 395.02M | 400.97M |
| Selling & admin expenses | 90.58M | 107.89M | 107.32M | 81.43M | 84.03M | 90.13M |
| Research & development | 179.93M | 179.24M | 198.42M | 178.07M | 170.39M | 172.43M |
| Operating profit | 107.72M | 30.09M | 157.68M | 192.14M | 113.88M | 96.77M |
| Pretax profit | 15.22M | 31.69M | 155.10M | 189.80M | 21.69M | 100.53M |
| Tax | -16.14M | 6.09M | 35.49M | 25.74M | -8.04M | 14.72M |
| Net profit | 31.37M | 25.59M | 119.60M | 164.06M | 29.73M | 85.80M |
| Basic EPS | 0 | 0 | 1 | 2 | 0 | 1 |
| Diluted EPS | 0.33 | 0.27 | 1.28 | 1.75 | 0.32 | 0.96 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.68B | 1.69B | 2.48B | 2.45B | 2.03B | 2.45B | 2.17B | 2.31B |
| Cash & ST investments | 711.04M | 714.94M | 1.40B | 972.59M | 808.76M | 1.03B | 1.02B | 1.22B |
| Inventory | 511.79M | 517.20M | 507.79M | 755.75M | 796.60M | 710.56M | 640.99M | 553.72M |
| Total assets | 5.81B | 6.56B | 7.22B | 7.51B | 6.69B | 6.55B | 5.93B | 5.83B |
| Total current liabilities | 435.61M | 539.00M | 681.58M | 675.13M | 555.76M | 1.23B | 783.18M | 712.76M |
| Short-term debt | 80.00K | 6.89M | -- | -- | 310.00K | 438.74M | -- | -- |
| Long-term debt | 920.94M | 1.57B | 1.74B | 2.05B | 2.05B | 1.55B | 1.55B | 1.55B |
| Total liabilities | 1,448,345,000.00 | 2,268,017,000.00 | 2,592,045,000.00 | 2,955,854,000.00 | 2,789,109,000.00 | 2,998,263,000.00 | 2,540,819,000.00 | 2,481,291,000.00 |
| Total equity | 4.36B | 4.29B | 4.63B | 4.55B | 3.90B | 3.56B | 3.39B | 3.34B |
| Retained earnings | -321.15M | 0 | 355.04M | 512.14M | 84.50M | -89.60M | -33.98M | 38.79M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.17B | 2.25B | 2.38B | 2.48B | 2.31B | 2.44B |
| Cash & ST investments | 1.02B | 1.17B | 1.10B | 1.32B | 1.22B | 1.33B |
| Inventory | 640.99M | 637.96M | 605.34M | 530.18M | 553.72M | 592.49M |
| Total assets | 5.93B | 6.00B | 6.10B | 6.16B | 5.83B | 5.94B |
| Total current liabilities | 783.18M | 798.33M | 804.58M | 675.70M | 712.76M | 687.69M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B |
| Total liabilities | 2,540,819,000.00 | 2,560,455,000.00 | 2,586,055,000.00 | 2,465,671,000.00 | 2,481,291,000.00 | 2,467,531,000.00 |
| Total equity | 3.39B | 3.44B | 3.51B | 3.70B | 3.34B | 3.47B |
| Retained earnings | -33.98M | -8.39M | 72.89M | 226.74M | 38.79M | 124.59M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 810.36M | 945.65M | 1.30B | 1.05B | 843.23M | 833.19M | 622.20M | 808.63M |
| Depreciation & amortization | 663.10M | 468.93M | 456.10M | 361.42M | 338.85M | 320.93M | 296.84M | 262.39M |
| Free cash flow | 589.43M | 781.54M | 1.11B | 835.78M | 684.28M | 705.96M | 484.60M | 679.56M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -596.79M | -464.93M | -472.49M | -1.11B | -829.24M | -363.14M | -320.60M | -497.06M |
| Ending cash balance | 711.38M | 715.61M | 1.40B | 972.81M | 808.94M | 1.05B | 1.02B | 1.22B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 199.18M | 182.95M | 83.99M | 265.43M | 276.26M | 139.49M |
| Depreciation & amortization | 70.78M | 67.46M | 66.71M | 65.52M | 62.70M | 50.14M |
| Free cash flow | 170.67M | 145.40M | 42.19M | 236.94M | 255.03M | 115.35M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -38.65M | -40.07M | -53.47M | -13.87M | -389.65M | 8.73M |
| Ending cash balance | 1.02B | 1.17B | 1.10B | 1.32B | 1.22B | 1.33B |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 2.91 | 7.73 | 16.44 | 22.51 | 2.44 | -1.89 | 1.60 | 10.06 |
| ROA %i | 2.18 | 5.41 | 10.65 | 14.03 | 1.45 | -1.06 | 0.89 | 5.77 |
| ROIC %i | 2.85 | 6.73 | 13.10 | 16.79 | 2.55 | -0.32 | 2.42 | 8.16 |
| 5-year avg ROE %i | 1.39 | 1.79 | 5.18 | 9.75 | 10.41 | 9.45 | 8.22 | 6.95 |
| EBIT margin %i | 4.39 | 14.06 | 21.98 | 26.79 | 5.41 | 3.79 | 3.88 | 12.82 |
| FCF / sales %i | 19.07 | 24.13 | 27.77 | 17.99 | 19.17 | 18.73 | 13.03 | 18.47 |
| Current ratioi | 3.87 | 3.14 | 3.64 | 3.63 | 3.65 | 1.99 | 2.77 | 3.24 |
| Quick ratioi | 2.55 | 2.04 | 2.76 | 2.33 | 2.05 | 1.18 | 1.81 | 2.27 |
| Debt / assetsi | 15.86 | 23.99 | 24.13 | 27.26 | 30.61 | 30.33 | 26.11 | 26.59 |
| LT debt / equityi | 21.12 | 36.51 | 37.64 | 44.96 | 52.48 | 43.56 | 45.67 | 46.32 |
| Interest coveragei | 3.09 | 7.54 | 11.74 | 19.65 | 2.82 | 2.06 | 1.84 | 6.45 |
| Revenue CAGR (3Y) %i | 5.78 | 2.22 | 10.53 | 14.56 | 3.29 | -2.08 | -7.15 | 1.01 |
| Net income CAGR (3Y) %i | -- | -- | -- | 98.00 | -32.43 | -- | -62.24 | 48.67 |
| FCF CAGR (3Y) %i | 16.55 | 51.64 | 24.15 | 12.34 | -4.33 | -14.13 | -16.61 | -0.23 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 1.60 | 2.33 | 6.30 | 9.62 | 10.06 | 11.56 |
| ROA %i | 0.89 | 1.30 | 3.46 | 5.62 | 5.77 | 6.69 |
| ROIC %i | 2.42 | 2.92 | 5.66 | 7.98 | 8.16 | 9.18 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 3.88 | 4.88 | 8.92 | 12.49 | 12.82 | 14.74 |
| FCF / sales %i | 13.03 | 16.08 | 14.59 | 15.92 | 18.47 | 17.82 |
| Current ratioi | 2.77 | 2.81 | 2.95 | 3.67 | 3.24 | 3.54 |
| Quick ratioi | 1.81 | 1.89 | 2.07 | 2.72 | 2.27 | 2.51 |
| Debt / assetsi | 26.11 | 25.83 | 25.41 | 25.13 | 26.59 | 26.08 |
| LT debt / equityi | 45.67 | 45.07 | 44.14 | 41.89 | 46.32 | 44.62 |
| Interest coveragei | 1.84 | 2.23 | 4.31 | 6.20 | 6.45 | 7.65 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Advanced Cellular Group (ACG) is the largest reported line at 60.73% of revenue, across 3 reported segments.
- High Performance Analog (HPA) follows at 26.29%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Advanced Cellular Group (ACG)60.73%
High Performance Analog (HPA)26.29%
Connectivity and Sensors Group (CSG)12.98%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.